![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Labeling Changes for Flexion’s Zilretta
FDA Approves Labeling Changes for Flexion’s Zilretta
January 7, 2020
The FDA approved Flexion Therapeutics’ supplemental NDA to update the product label for Zilretta (triamcinolone acetonide extended-release injectable suspension) for the treatment of osteoarthritis knee pain.
The agency allowed the removal of language which stated that Zilretta was “not intended for repeat administration.” The updated label states that the “efficacy and safety of repeat administration of Zilretta have not been demonstrated.”
The drug was originally approved in October 2017 as the first extended-release intra-articular therapy for patients with osteoarthritis-related knee pain.
Upcoming Events
-
21Oct